Physician profile
Kyle C Levitt
NPI 1912427923
$1,242.38
in general payments reported to CMS, 2019-2025
15 companies · $34.82 in 2025
The $34.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $121 · 2023: $346 · 2024: $640 · 2025: $34.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $349.02 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $248.73 | 2023 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $178.96 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $101.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.28 | 2023 | |
| Lilly USA, LLC | $88.81 | 2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $37.66 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $26.60 | 2024 | Rexulti |
| Exact Sciences Corporation | $20.21 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $17.53 | 2024 | Airsupra |
| Glaxosmithkline, LLC. | $17.32 | 2025 | Arexvy, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.86 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $15.62 | 2024 | |
| Merck Sharp & Dohme LLC | $15.39 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Irhythm Technologies, INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.